CTIS2024-513501-31-00进行中（未招募）1 期
An Open Label Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients with Stargardt’s Macular Degeneration - LTS13588
Sanofi-Aventis Recherche & Developpement0 个研究点目标入组 27 人开始时间: 2024年7月30日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 27
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 64（—）
- 性别
- All
入选标准
- •Provide signed and dated written informed consent and any locally required authorization eg, HIPAA, Must have been enrolled in protocol TDU13583, Must have received a subretinal injection of SAR422459, Must have completed protocol TDU13583 to Week 48 or undergone an early discontinuation visit
排除标准
- •Did not receive SAR422459 as part of the TDU13583 protocol
研究者
相似试验
进行中（未招募）
1 期
Phase I/II Follow-up Study of SAR422459 in Patients with Stargardt's Macular DegeneratioStargardt Macular Dystrophy, also known as fundus flavimaculatus or Stargardt disease.MedDRA version: 20.1Level: PTClassification code 10062766Term: Stargardt's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2012-001990-95-FRsanofi-aventis recherche et développement27
进行中（未招募）
1 期
Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid PolyneuropathyHereditary Transthyretin-Mediated Amyloid PolyneuropathyMedDRA version: 20.0Level: LLTClassification code 10057949Term: Familial amyloid polyneuropathySystem Organ Class: 100000004850EUCTR2021-001427-40-CYIonis Pharmaceuticals, Inc.165
进行中（未招募）
1 期
Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid PolyneuropathyEUCTR2021-001427-40-FRIonis Pharmaceuticals, Inc.165
进行中（未招募）
1 期
Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid PolyneuropathyHereditary Transthyretin-Mediated Amyloid PolyneuropathyMedDRA version: 20.0Level: LLTClassification code 10057949Term: Familial amyloid polyneuropathySystem Organ Class: 100000004850EUCTR2021-001427-40-ESIonis Pharmaceuticals, Inc.165
进行中（未招募）
1 期
Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid PolyneuropathyHereditary Transthyretin-Mediated Amyloid PolyneuropathyMedDRA version: 20.0Level: LLTClassification code 10057949Term: Familial amyloid polyneuropathySystem Organ Class: 100000004850EUCTR2021-001427-40-SEIonis Pharmaceuticals, Inc.165